Results 31 to 40 of about 12,171 (216)

Cholestyramine Use for Rapid Reversion to Euthyroid States in Patients with Thyrotoxicosis [PDF]

Endocrinology and Metabolism, 2016
Cholestyramine (CS) is an ion exchange resin, which binds to iodothyronines and would lower serum thyroid hormone level. The use of CS added to conventional antithyroid drugs to control thyrotoxicosis has been applied since 1980's, and several studies ...
Jeonghoon Ha, Kwanhoon Jo, Borami Kang, Min-Hee Kim, Dong-Jun Lim   +4 more
doaj   +1 more source

CD1a expression in psoriatic skin following treatment with propylthiouracil, an antithyroid thioureylene [PDF]

, 2003
BackgroundThe antithyroid thioureylenes, propylthiouracil (PTU) and methimazole (MMI), are effective in the treatment of patients with plaque psoriasis. The mechanism of action of the drugs in psoriasis is unknown.
Alan N Elias, Vandana S Nanda, Ronald J Barr, KG Linden, MW Greaves, HS Javitz, AN Elias, AN Elias, AN Elias, AN Elias, K Kose, G Aust, MK Gupta, LD Kohn, LD Kohn, N Ohtani, R Wilson, AN Elias, BJ Nickoloff, K Hong, J Cheng, PS Friedmann, J Czernielewski, RS Dawe, MA de Rie, M Tamura, S Athanasas-Platsis, JL Jones, JM Dobmeyer, DG Albertson, F Calabi, EM Beckman, T Fredriksson, P Asawanonda, O Larko, S Ebner, C Caux, AS Breathnach, T Plath, FO Nestle, A Lenz, J Czernielewski, J Kanitakis   +42 more
core   +1 more source

A case of thyrotoxic periodic paralysis as initial manifestation of Graves' disease in a 16-year-old Korean adolescent [PDF]

Annals of Pediatric Endocrinology & Metabolism, 2014
Thyrotoxic periodic paralysis (TPP) is a rare complication of hyperthyroidism, with recurrent muscle paralysis and hypokalemia that are caused by an intracellular shift of potassium.
Se Yong Jung, Kyung Chul Song, Jae Il Shin, Hyun Wook Chae, Ho-Seong Kim, Ah Reum Kwon   +5 more
doaj   +1 more source

Graves' ophthalmopathy [PDF]

, 2009
A 40-year-old woman who recently received a diagnosis of Graves' disease comes for a follow-up visit. She has been taking methimazole, at a dose of 10 mg daily, and is now euthyroid, but for the past 3 months, she has had bothersome eye symptoms ...
Bartalena, Luigi, Tanda, Maria Laura Piera   +1 more
core   +1 more source

Relapse Rate and Clinical Risk Factors Affecting the Treatment of Graves’ Disease

Siriraj Medical Journal, 2021
Objective: To determine the relapse rate of Graves’ disease (GD) and identify important clinical risk factors for relapse. Materials and Methods: This was a 10-year retrospective cohort study.
Phatharaporn Kiatpanabhikul
doaj   +1 more source

Hyperthyroidism in pregnancy: evidence and hypothesis in fetal programming and development

Endocrine Connections, 2021
The management of hyperthyroidism in pregnant patients has been a topic of raised clinical awareness for decades. It is a strong recommendation that overt hyperthyroidism of Graves’ disease in pregnant women should be treated to prevent complications ...
Stine Linding Andersen, Stig Andersen
doaj   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Pharmacodynamic Response to Anti-thyroid Drugs in Graves' Hyperthyroidism

Frontiers in Endocrinology, 2020
Objective: Graves' disease is the commonest cause of hyperthyroidism in populations with sufficient dietary iodine intake. Anti-thyroid drugs (ATD) are often used as the initial treatment for Graves' hyperthyroidism, however there is a paucity of data ...
Ali Abbara, Ali Abbara, Sophie A. Clarke, Sophie A. Clarke, Rosalind Brewster, Alexia Simonnard, Pei Chia Eng, Maria Phylactou, Deborah Papadopoulou, Deborah Papadopoulou, Chioma Izzi-Engbeaya, Chioma Izzi-Engbeaya, Amir H. Sam, Amir H. Sam, Florian Wernig, Eliza Jonauskyte, Alexander N. Comninos, Alexander N. Comninos, Karim Meeran, Karim Meeran, Tom W. Kelsey, Waljit S. Dhillo, Waljit S. Dhillo   +22 more
doaj   +1 more source

Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study [PDF]

, 2007
In most trials, at least 30-60% of patients with Graves' disease treated with antithyroid drugs relapse within 2 years after therapy withdrawal. At present, there are no prognostic parameters available early in treatment to indicate patients likely to ...
AGABITI ROSEI E, AGOSTI B, CAPPELLI C, CASTELLANO M, DE MARTINO E, DELBARBA A, GANDOSSI E, PIROLA I, PIZZOCARO C   +8 more
core   +1 more source

Fulminant type 1 diabetes with high‐titer anti‐glutamic acid decarboxylase antibodies: Likely rapid progression from stage 2 to 3

Journal of Diabetes Investigation, EarlyView.
Abstract A 61‐year‐old man visited our hospital with a sudden onset of polydipsia and polyuria occurring 5 days prior, accompanied by a 5‐kg weight loss. A month prior, his glycated hemoglobin level was 6.2%. Precisely 8 days before the first visit, he had a fever, and hyperglycemic symptoms began shortly thereafter.
Megumi Sato, Junnosuke Miura, Hikaru Oyatsu, Yuka Yoshida, Shota Mochizuki, Michio Otsuki, Tomoko Nakagami   +6 more
wiley   +1 more source